Dermatology | Phase I Developments | UNITED STATES

Rapt Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting

Lead Product(s): RPT193

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

In multiple preclinical studies of allergic skin inflammation, once-daily dosing of RPT193 demonstrated efficacy and reduction of Th2 cytokines comparable to treatment with currently available biologics that work by blocking interleukin-4 (IL-4) and IL-13.

Histogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Histogen Announces Investigational New Drug Application Amendment for HST 001

Lead Product(s): HST 001

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

Details:

Histogen has submitted IND amendment with the U.S. FDA for the initiation of a Phase 1b/2a clinical trial of its lead program, HST 001 for the treatment of androgenic alopecia in men.

Histogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

Lead Product(s): HST 001

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Conatus Pharmaceuticals

Deal Size: $135.1 million Upfront Cash: Undisclosed

Deal Type: Merger January 28, 2020

Details:

Proposed merger creates regenerative medicine company with three clinical-stage product candidates and combined company capitalization expected to support operations into 2021.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline t...

Lead Product(s): EDP1815

Therapeutic Area: Dermatology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Evelo has agreed upon the design of the EDP1815 Phase 2 clinical trial with global regulatory agencies. The dose ranging study will evaluate three doses of EDP1815 versus placebo in 180 individuals.

Find

Find Dermatology Drugs in Phase I Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Rapt Therapeutics

RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting

Histogen

Histogen Announces Investigational New Drug Application Amendment for HST 001

Histogen

Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

Evelo Biosciences

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline t...